Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Biotech's Platform Technologies Lure Big Pharma

Bio/Technology volume 13, pages 945–947 (1995)Cite this article

Abstract

Sandoz's purchase of Genetic Therapy Inc. is yet more confirmation that big pharma knows the value of hot new drug technology—even if Wall Street doesn't

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Culver, K. 1995. US005399346A—An Ex Vivo Gene Therapy Patent? Gene Therapy Newsletter 10 (May 1995):1–3.

    Google Scholar 

  2. Anon. 1995. Process for the preparation of human cells expressing a therapeutic protein. Exp. Opin. Ther. Patents 5: 696–698.

Download references

Author information

Authors and Affiliations

  1. articles editor for Bio/Technology,

    John Hodgson

Authors
  1. John Hodgson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hodgson, J. Biotech's Platform Technologies Lure Big Pharma. Nat Biotechnol 13, 945–947 (1995). https://doi.org/10.1038/nbt0995-945

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0995-945

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing